This blog is a news aggregation of life extension related articles coming from reputable sources.

Looking for our regular content? click here

I spent an interesting few days last week attending RAADfest, and came away somewhat optimistic that this strange collision of subcultures may herald an acceleration in the adoption of solid science and working therapies on the part of the anti-aging marketplace, accompanied by a driving out of the ineffective nonsense and fraud of past decades….

25 Sep 2018 25 Sep 2018 Researchers Generate Esophagus Organoids from Pluripotent Stem Cells Loading… Loading… Every tissue requires a different recipe for the production of a functioning structure from the starting point of a few cells: different signals, different environment, different timing. Researchers in the heavily funded tissue engineering community are working their way…

25 Sep 2018 25 Sep 2018 An Update on Dkk1 as a Therapeutic Target in Alzheimer’s Disease Loading… Loading… Six years ago, researchers reported that dkk1 appears to be involved in the destruction of synapses in Alzheimer’s disease. More recent work expands the understanding of dkk1 in this context, placing it in a positive feedback…

IMAGE: These images from scientists at Cincinnati Children’s show hematopoietic stem cells (blood stem cells) from donor laboratory mice. The donor stem cell harvested from a mouse treated with the preclinical… view more  Credit: Cincinnati Children’s CINCINNATI – Two recent studies in the journal Leukemia present a new approach for bone marrow donation and transplant that…

Driver genes in different metastases from the same patient are remarkably similar, providing optimism for the success of future targeted therapies, according to a published study by Science. The report, “Minimal Functional Driver Gene Heterogeneity Among Untreated Metastases,” looked at data from samples that have spread from the site of origin to another part of…

IMAGE: D. Ross Camidge, M.D., Ph.D., and colleagues show 51 percent reduction in risk of death over course of phase III ALTA-1 trial with brigatinib compared with cirzotinib. view more  Credit: University of Colorado Cancer Center Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of…

IMAGE: Dr. Nancy DeMore (center) leads a multidisciplinary tumor board meeting at MUSC Hollings Cancer Center. view more  It’s early morning and a team of more than 20 professionals cram around a long table in a dark room, peering at slide after slide of black-and-white mammogram images crossing the screen. All the stories are different. The…

IMAGE: Brian Helfand, MD, PhD, a urologist with NorthShore’s Center for Personalized Medicine. view more  view more  (Evanston, IL) – September 25, 2018 – NorthShore University HealthSystem’s (NorthShore) Center for Personalized Medicine and Ambry Genetics Corporation (Ambry), announced today the launch of AmbryScore for prostate cancer risk. AmbryScore is the first commercially available polygenic risk score…

IMAGE: This is Matthew Bochman. view more  Credit: Zach Donnell BLOOMINGTON, Ind. — A new study from molecular biologists at Indiana University has identified cellular processes that appear to supercharge both the growth and shrinkage of the chemical “caps” on chromosomes associated with aging, called telomeres. The work, focused on two enzymes in yeast, could lead…

LOS ANGELES (Sept. 25, 2018) — A newly developed drug can prevent the most common type of pancreatic cancer from growing and spreading in laboratory mice, according to a study led by Cedars-Sinai. The study, published recently in the journal Gastroenterology, also demonstrated in mice that the drug, called Metavert, may prevent patients from developing…

IMAGE: This is Maurizio Pellecchia of UC Riverside in the lab. view more  Credit: Carrie Rosema Recently, a research team led by Maurizio Pellecchia at the University of California, Riverside, discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases. The team was…

IMAGE: Harnessing Artificial Intelligence to Improve Drug Combination Design and Personalized Medicine view more  Credit: Zac Goh A new auto-commentary published in SLAS Technology looks at how an emerging area of artificial intelligence, specifically the analysis of small systems-of-interest specific datasets, can be used to improve drug development and personalized medicine. The auto-commentary builds on a…

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD